An2 Therapeutics logo

An2 Therapeutics Share Price (NASDAQ: ANTX)

$1.09

-0.01

(-0.91%)

Last updated on

Check the interactive An2 Therapeutics Stock chart to analyse performance

An2 Therapeutics stock performance

as on August 30, 2025 at 1:26 am IST

  • Today's Low:$1.09
    Today's High:$1.13

    Day's Volatility :3.54%

  • 52 Weeks Low:$0.98
    52 Weeks High:$1.68

    52 Weeks Volatility :41.79%

An2 Therapeutics Stock Returns

PeriodAn2 Therapeutics, Inc.Index (Russel 2000)
3 Months
6.6%
0.0%
6 Months
1.35%
0.0%
1 Year
2.73%
0.0%
3 Years
-92.24%
-4.7%

An2 Therapeutics, Inc. Key Stats

Check An2 Therapeutics key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$1.1
Open
$1.13
Today's High
$1.13
Today's Low
$1.09
Market Capitalization
$30.1M
Today's Volume
$15.5K
52 Week High
$1.675
52 Week Low
$0.975
Revenue TTM
$0.0
Earnings Per Share (EPS)
$-1.25
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-44.71%

Stock Returns calculator for An2 Therapeutics Stock including INR - Dollar returns

The An2 Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

An2 Therapeutics investment value today

Current value as on today

₹1,01,744

Returns

₹1,744

(+1.74%)

Returns from An2 Therapeutics Stock

₹3,540 (-3.54%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards An2 Therapeutics Stock

-38%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for An2 Therapeutics Stock from India on INDmoney has decreased by -38% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in An2 Therapeutics, Inc.

  • Name

    Holdings %

  • Almitas Capital LLC

    4.80%

  • Vanguard Group Inc

    3.78%

  • Adage Capital Partners Gp LLC

    3.65%

  • Pfizer Inc

    2.61%

  • Peapod Lane Capital LLC

    2.13%

  • Stonepine Capital Management Llc

    1.99%

Analyst Recommendation on An2 Therapeutics Stock

Rating
Trend

Buy

    72%Buy

    27%Hold

    0%Sell

Based on 11 Wall street analysts offering stock ratings for An2 Therapeutics(by analysts ranked 0 to 5 stars)

An2 Therapeutics Share Price Target

What analysts predicted

Upside of 37.61%

Target:

$1.50

Current:

$1.09

An2 Therapeutics share price target is $1.50, a slight Upside of 37.61% compared to current price of $1.09 as per analysts' prediction.

An2 Therapeutics Stock Insights

  • Price Movement

    In the last 3 years, ANTX stock has moved down by -92.6%
  • ANTX vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.9% return, outperforming this stock by 69.9%
  • ANTX vs ALNY (3 yr)

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 112.6% return, outperforming this stock by 205.2%

An2 Therapeutics Technicals Summary

Sell

Neutral

Buy

An2 Therapeutics is currently in a neutral trading position according to technical analysis indicators.

An2 Therapeutics, Inc. Vs Peers

Returns
Ratio's
Overview
Company Name1 Month6 Month1 Year3 Years5 Years
An2 Therapeutics, Inc. logo
6.6%
1.35%
2.73%
-92.24%
-92.66%
Regeneron Pharmaceuticals, Inc. logo
6.48%
-15.2%
-50.31%
-3.3%
-2.01%
Beone Medicines Ltd logo
1.77%
24.81%
62.78%
79.11%
29.69%
Vertex Pharmaceuticals Incorporated logo
-14.45%
-19.13%
-17.84%
34.68%
41.87%
Alnylam Pharmaceuticals, Inc. logo
13.79%
83.28%
75.87%
111.28%
242.25%

About An2 Therapeutics, Inc.

AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has various research programs targeting the development of novel compounds in oncology and infectious disease based on its boron chemistry platform. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize compounds and products, including epetraborole for the treatment, diagnosis, or prevention of various human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize compounds and products comprising epetraborole in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Organization
An2 Therapeutics
Employees
22
CEO
Mr. Eric E. Easom
Industry
Services

Key Management of An2 Therapeutics, Inc.

NameTitle
Mr. Eric E. Easom
Co-Founder, CEO, President & Chairman of the Board
Mr. Joseph S. Zakrzewski
Co-Founder & Independent Chairman of the Board
Ms. Lucy O. Day CPA
CFO, Principal Financial Officer & Principal Accounting Officer
Mr. Joshua M. Eizen J.D.
Chief Legal Officer, COO & Corporate Secretary
Dr. George Harrison Talbot FACP, M.D.
Co-Founder & Senior Clinical Advisor
Dr. Michael R. K. Alley Ph.D.
Co-Founder, Senior VP of Research Fellow & Head of Biology
Dr. Sanjay Chanda Ph.D.
Chief Development Officer
Dr. Stephen David Prior Ph.D.
Chief Strategy Officer
Mr. Vince Hernandez
Senior VP of Research & Head of Chemistry

Important FAQs about investing in ANTX Stock from India :

What is An2 Therapeutics share price today?

An2 Therapeutics share price today is $1.09 as on at the close of the market. An2 Therapeutics share today touched a day high of $1.13 and a low of $1.09.

What is the 52 week high and 52 week low for An2 Therapeutics share?

An2 Therapeutics share touched a 52 week high of $1.68 and a 52 week low of $0.98. An2 Therapeutics stock price today i.e. is closed at $1.09, lower by 34.93% versus the 52 week high.

How to invest in An2 Therapeutics Stock (ANTX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for An2 Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in An2 Therapeutics Shares that will get you 1.3761 shares as per An2 Therapeutics share price of $1.09 per share as on August 30, 2025 at 1:26 am IST.

What is the minimum amount required to buy An2 Therapeutics Stock (ANTX) from India?

Indian investors can start investing in An2 Therapeutics (ANTX) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in An2 Therapeutics stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on An2 Therapeutics share’s latest price of $1.09 as on August 30, 2025 at 1:26 am IST, you will get 9.1743 shares of An2 Therapeutics. Learn more about fractional shares .

What are the returns that An2 Therapeutics has given to Indian investors in the last 5 years?

An2 Therapeutics stock has given -92.66% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?